Abstract
Cold Spring Harbor Laboratory Conference on Cell Death
August 15 - 19, 2017
The field of cell death encompasses many molecular and biochemical processes that were evolutionarily
selected to promote self-elimination of cells. Programmed cell death is required for normal development and
tissue homeostasis. Abnormalities in the regulation of cell death contribute to a wide variety of human
disorders, including cancer, AIDS, stroke, autoimmunity and neurodegenerative disorders. Most if not all
cells have the capacity to commit suicide, and key components of various cell death programs have been
conserved in lower organisms, thereby providing powerful model systems for study. Some of the genes that
regulate programmed cell death include oncogenes and tumor suppressor genes, providing a link between
deregulation of cell death pathways and cancer. Many viruses encode genes that promote or inhibit cell
death, indicating that subversion of this cellular process is an aspect of the pathology of virus infections.
Rapid advancements in recent years have led to the identification of numerous genes and gene products
involved in controlling different aspects of cellular death, and the biochemical pathways that regulate cell
death have begun to emerge. New evidence strengthens the link between cell death mechanisms and
mitochondrial energetics. Model systems have permitted directed mutagenesis of cell death regulatory
genes mammals, invertebrates and lower organisms, demonstrating the role of cell death in a wide range of
cellular responses and disease states. The development of cell-free assays and the reconstitution of
biochemical reactions from purified components have served to delineate some of the details of cell death
pathways. Researchers in the field of cell death are a diverse group whose interests span invertebrate to
mammalian developmental biology, neurobiology, tumorigenesis, immunology, infectious diseases,
biochemistry, cell biology, structural biology, cell cycle control, transcription regulation, receptor signaling
and DNA damage pathways. The CSHL conference on Cell Death will be held on August 15 - 19, 2017.
The objective of this conference is to bring together researchers working in the diverse aspects of
programmed cell death and to facilitate new discoveries. The meeting plan includes an opening address,
eight plenary and two poster sessions, in which participation by junior scientists will be facilitated. The
overall goal is to create a meeting environment suitable for the open exchange of information and ideas that
will foster advancement of the field toward a full understanding and development of new therapeutic
approaches.
Public Health Relevance Statement
CSHL Conference on Cell Death
Lay Narrative
Most if not all cells in our bodies have the capacity to commit suicide, and key components of cell death
have been conserved in lower organisms, providing powerful model systems for scientists to
study. Abnormalities in the regulation of cell death contribute to a wide variety of human disorders, including
cancer, AIDS, stroke, autoimmunity, aging, and neurodegenerative disorders. In particular, many of the
genes that regulate cell death are known to either promote or suppress cancer progression, and therefore
represent potential targets for the development of new anticancer therapies. This biennial conference series
will continue to address the latest advances in the field.
No Sub Projects information available for 1R13AG056125-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R13AG056125-01
Patents
No Patents information available for 1R13AG056125-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R13AG056125-01
Clinical Studies
No Clinical Studies information available for 1R13AG056125-01
News and More
Related News Releases
No news release information available for 1R13AG056125-01
History
No Historical information available for 1R13AG056125-01
Similar Projects
No Similar Projects information available for 1R13AG056125-01